Manish P Sharma

US Patent:

20020048066, Apr 25, 2002

Filed:

May 15, 2001

Appl. No.:

09/858345

Inventors:

Neophytos Antoniades - Leonia NJ, US
Aleksandra Boskovic - Highland Park NJ, US
Manish Sharma - North Brunswick NJ, US
Eric Buckland - Hickory NC, US
Douglas Butler - Painted Post NY, US
Ming-Jun Li - Horseheads NY, US
Thomas McNamara - Corning NY, US
David Pastel - Horeseheads NY, US
Mark Soulliere - Corning NY, US
Michael Yadlowsky - Corning NY, US

International Classification:

H04J014/02

US Classification:

359/128000, 359/127000

Abstract:

A wavelength selective optical cross-connect includes a first demultiplexor feeding into individually removable modules that in turn feed a first multiplexor, such that the cross-connect is expandable and repairable on a wavelength or waveband basis. The modules desirably include multiple optical components in the optical path, with components in each module matched to others in that module to provide module-to-module variation below that of the variation in module components. The modules desirably include an additional demultiplexor and multiplexor. The modules also desirably include wavelength or narrowband amplification together with power equalization. The modules may also include a switch fabric. Alternatively, the switch fabric may be provided in the form of a separate removable switch module or modules, with various technologies employed in various switch modules, including manual switching with automatic connection discovery, with simple plug-in upgradeability to modules having automatic or remotely actuated switching.

US Patent:

20130114957, May 9, 2013

Filed:

Nov 3, 2011

Appl. No.:

13/288887

Inventors:

Jonathan D. HOMA - Livingston NJ, US
Manish Sharma - Morgan Hill CA, US

International Classification:

H04J 14/02

US Classification:

398 48

Abstract:

An optical switching device with a switch-and-select architecture uses a single multi-port optical channel router, such as a wavelength selective switch, as a bidirectional switching device. The optical switching device includes the multi-port optical channel router and optical circulators coupled to the input/output ports of the multi-port optical channel router. The optical circulators couple one or more output ports and one or more input ports of the optical switching device to the input/output ports of the optical channel router so that the optical channel router provides symmetric, bi-directional switching at an optical network node.

US Patent:

20220410129, Dec 29, 2022

Filed:

Dec 11, 2020

Appl. No.:

17/756194

Inventors:

- Florham Park NJ, US
Manish SHARMA - Iselin NJ, US
Glenn D. SVOBODA - Iselin NJ, US
Matthew J. SCHLADT - Iselin NJ, US
Yuxuan XIN - Plainsboro NJ, US

International Classification:

B01J 23/46
B01J 21/04
B01J 23/10
B01J 37/00
B01J 37/02
B01J 37/08
B01J 35/00
B01J 35/02
B01J 35/10
B01D 53/94
F01N 3/28
F01N 3/10

Abstract:

The present invention relates to a catalyst washcoat composition comprising a slurry comprising at least one platinum group metal and/or at least one non-platinum group metal supported on at least one support; and at least one pore forming agent having a particle size ranging from 100 nm to 5.0 μm, wherein the pore forming agent is selected from carbon nano-tubes, carbon nano-fibres, activated carbon, resins, cellulose powder, and polymer spheres. The present invention also provides a catalyst article for capturing particulate matter of size ranging from 1.0 nm to 100 μm, said article comprising the catalyst washcoat deposited on a substrate and calcined to form pores of which 50%-100% have a pore size ranging from 100 nm to 5.0 μm.

US Patent:

20210206865, Jul 8, 2021

Filed:

Dec 4, 2020

Appl. No.:

17/112564

Inventors:

- Tarrytown NY, US
David Sternberg - New York NY, US
Manish Sharma - Scarsdale NY, US
Lieve Adriaens - Westfield NJ, US

International Classification:

C07K 16/28

Abstract:

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.